Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added ...
The Center for Probe Development and Commercialization (CPDC) has entered a development, manufacturing and supply agreement with CellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. CPDC will develop and manufacture CellBion's drug product for Phase II clinical supply in South Korea with the goal of expanding into North America.